Sept 2 (Reuters) - Arrowhead Pharmaceuticals ( ARWR )
said on Tuesday it will receive up to $2 billion from Novartis
for an exclusive worldwide license to its experimental
therapy that targets neuromuscular conditions such as
Parkinson's Disease.